Pluristem Appoints Prof. Varda Shalev MD and Mr. Doron Birger to Join its Board of Directors
July 19, 2021 07:00 ET | Pluristem Therapeutics, Inc.
HAIFA, Israel, July 19, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI), a leading biotechnology company, today announced the Board of Director appointments of Prof....
Pluristem Therapeutics Inc. Logo
Pluristem Brings ARDS Associated with COVID-19 Phase II Studies to Clinical Readout
July 08, 2021 07:10 ET | Pluristem Therapeutics, Inc.
The company will analyze data based on patients enrolled to date in COVID-19 Phase II studies in U.S., Europe and IsraelTopline results are expected during the fourth quarter of 2021 HAIFA, Israel,...
Pluristem Therapeutics Inc. Logo
Pluristem to Receive €20M Non-Dilutive Funding from the European Investment Bank
May 25, 2021 07:00 ET | Pluristem Therapeutics, Inc.
HAIFA, Israel, May 25, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI) (the “Company”), a leading biotechnology company, today announced the receipt of a “Disbursement...
Pluristem Therapeutics Inc. Logo
Pluristem reports positive topline Phase I results in innovative hematology program, which is first to study PLX-R18 in humans
April 29, 2021 07:00 ET | Pluristem Therapeutics, Inc.
New therapy has potential to generate improved blood counts in all three blood cell lineages, a meaningful advantage over existing treatmentsThe company will conduct an analyst and investor call on...
Pluristem Therapeutics Inc. Logo
Pluristem Therapeutics Inc. Announces $30 Million Registered Direct Offering
February 02, 2021 08:30 ET | Pluristem Therapeutics, Inc.
HAIFA, Israel, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic...
Pluristem Therapeutics Inc. Logo
Pluristem Announces Uplisting to the Nasdaq Global Market®
January 27, 2021 07:00 ET | Pluristem Therapeutics, Inc.
HAIFA, Israel, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic...
Pluristem Announces Appointments of Two Directors to Board
January 06, 2021 07:00 ET | Pluristem Therapeutics, Inc.
HAIFA, Israel, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic...
Pluristem Therapeutics Inc. Logo
Pluristem Enters Collaboration With Pharmaceutical Company Innovare R&D to Expand Pluristem’s ARDS Associated With COVID-19 Program to Mexico
December 29, 2020 07:00 ET | Pluristem Therapeutics, Inc.
HAIFA, Israel, Dec. 29, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic...
Pluristem Therapeutics Inc. Logo
Pluristem Announces DMC Recommendation Following Interim Analysis of its Phase III CLI Study
December 09, 2020 04:00 ET | Pluristem Therapeutics, Inc.
The CLI study is unlikely to meet its primary endpoint by the time of the final analysis Substantial low number of events in the placebo group in the CLI study decreased the statistical power of the...
Pluristem Therapeutics Inc. Logo
Pluristem to Present Initial Results from Its Phase I HCT Study with PLX-R18 Demonstrating Safety and Efficacy at the ASH Annual Meeting
November 18, 2020 07:00 ET | Pluristem Therapeutics, Inc.
PLX-R18 demonstrated significant clinical improvements in Hb, ANC, and PLT among the high-dose cohortPLX-R18 was found to be safe and well-toleratedTopline results from the full Phase I clinical trial...